Mar 15, 2017Science and Technology
Chimeric antigen receptor T cells (CAR-T cells) Patent

A composition of matter and method patent issued to UCSF will be used to generate new cancer therapies using modified immune cells via an exclusive license to one company. 

Cell Design Labs Announces Issuance Of Broad Patent For Programmable Car T Cells To Treat Cancer And Other Diseases
Share
Be the first to comment.